Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Kazianka, L; Pichler, A; Agreiter, C; Rohrbeck, J; Kornauth, C; Porpaczy, E; Sillaber, C; Sperr, WR; Gleixner, KV; Hauswirth, A; Jäger, U; Valent, P; Jonak, C; Porkert, S; Exner, R; Willenbacher, W; Wolf, D; Neumeister, P; Prochazka, K; Deutsch, A; Greil, R; Schmitt, C; Ristl, R; Mayerhoefer, M; Simonitsch-Klupp, I; Pemovska, T; Staber, PB.
Comparing functional and genomic-based precision medicine in blood cancer patients.
Hemasphere. 2025; 9(4):e70129
Doi: 10.1002/hem3.70129
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Staber Philipp
- Co-authors Med Uni Graz
- Deutsch Alexander
- Neumeister Peter
- Prochazka Katharina
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Tumor-agnostic precision medicine (PM) strategies promise to support treatment decisions in relapsed/refractory blood cancer patients. Genomic-based PM (gPM) and drug screening-based functional PM (fPM) currently represent the most prominent PM methodologies. In this study, we report the feasibility analysis of the first 55 patients enrolled in the multicentric, randomized controlled EXALT-2 trial (NCT04470947) comparing treatment recommendations of gPM, fPM, and physicians' choice (PC) head to head. In 54 patients (98%), the diagnostic workflow was successfully implemented, resulting in treatment recommendations for 42 patients (76%), of whom 29 (69%) received the suggested individualized treatments. Actionable targets were identified in 65% by gPM and 80% by fPM (64% microscopy-based, 86% flow cytometry-based fPM). The median time to report was shorter for fPM than for gPM testing. The two strategies revealed overlapping drug targets in 60% of cases. Both, gPM and fPM can efficiently be integrated into the clinical routine to guide therapy decisions for the majority of patients.